National Center for Health Statistics. Detailed Tables for the National Vital Statistics Report; Deaths: final Data for 2010, (Accessed July 20,2014 at http://www.cdc.gov/ nchs/data/deaths_2010_release.pdf.)
Jack CR, Albert MS, Knopman DS, et al. Inroduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:257-62.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263-9.
Albert MS, DeKosky ST, Dickson D, et al., The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270-9.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recom- mendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280-92.
Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-47.
Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 2008;131:1630-45.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh com- pound-B. Ann Neurol 2004;55:306-19.
Rowe CC, Villemagne VL. Brain Amyloid Imaging.J Nucl Med 2011;52:1733-40.
Rowe CC, NG S, Ackermann U, et al., Imaging b-amyloid burden in aging and dementia. Neurology 2007;68;1718-25.
Edison P, Archer HA, Hinz R, et al. Amyloid hypome- tabolism and cognition in Alzheimer disease: an [11C] PIB and [18F]FDG PET study. Neurology 2007;68:501-98.
Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PET amyloid ligan [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-80.
Nordberg A. PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol 2004; 3: 519-27.
Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patient with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010;23: 185-98.
Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4’-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-92.
Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002;12:295-8.
International Atomic Energy Agency. Cyclotron produced radionuclides: physical characteristics and production methods. Technical Reports Series No. 468. 2009 (Accessed July 25, 2014 at http://www-pub.iaea.org/ MTCD/publications/PDF/trs468_web.pdf).
